Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Tryptamine Therapeutics ( (AU:ENP) ).
Entropy Neurodynamics Limited has disclosed a change in director Jason Carroll’s interests, with Carroll purchasing 1 million ordinary fully paid shares on-market for A$30,000. Following the transaction, his direct holding increased to 54.3 million ordinary shares, in addition to substantial existing holdings of various options, underscoring continued insider confidence and potentially reinforcing investor perception of alignment between management and shareholder interests.
The most recent analyst rating on (AU:ENP) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, associated with Tryptamine Therapeutics, is an ASX-listed company involved in developing therapeutics, with its capital structure comprising ordinary fully paid shares and a range of performance and director options with various exercise prices and expiries. The company operates in the biotechnology/pharmaceutical sector, focusing on value creation via equity and option-based incentives aligned with management and director participation.
Average Trading Volume: 2,238,973
Technical Sentiment Signal: Sell
Current Market Cap: A$51.65M
For detailed information about ENP stock, go to TipRanks’ Stock Analysis page.